Search

Your search keyword '"Kos Kudla, B"' showing total 14 results
Start Over Author "Kos Kudla, B" Language undetermined
14 results on '"Kos Kudla, B"'

1. Unmet Needs in Appendiceal Neuroendocrine Neoplasms

Author

Toumpanakis, C, Fazio, N, Janson, ET, Horsch, D, Pascher, A, Reed, N, O'Toole, D, van Dijkum, EN, Partelli, S, Rinke, A, Kos-Kudla, B, Costa, F, Pape, UF, Grozinsky-Glasberg, S, Scoazec, JY, Detlef, B, Rudolf, A, Eric, B, Lisa, B, Ivan, B, Jaume, C, Martyn, C, Jie, C, Frederico, C, Anne, C, Jaroslaw, BC, de Herder, W.W., Massimo, F, Jenny, F, Nicola, F, Diego, F, Andrea, F, Rocio, GC, Simona, G, Vera, G, Ashley, G, Dieter, H, Robert, J, Gregory, K, Gunter, K, Peter, KU, Beata, KK, Guenter, JK, Krenning, EP, Matthew, K, Steven, WJL, Elisabeth, NV, Manuel, OJ, Dermot, O, Ulrich-Frank, P, Di Stefano, P, Ellen, PM, Marc, P, John, R, Nicholas, R, Guido, R, Anja, R, Philippe, R, Halfdan, S, Anders, S, Jean-Yves, S, Babs, GT, Eva, TJ, Christos, T, Juan, V, Marie-Pierre, V, Staffan, W, Bertram, W, Internal Medicine, ENETS 2016 Munich Advisory Board, Toumpanakis, C., Fazio, N., Tiensuu Janson, E., Horsch, D., Pascher, A., Reed, N., O'Apostoole, D., Nieveen Van Dijkum, E., Partelli, S., Rinke, A., Kos-Kudla, B., Costa, F., Pape, U. -F., Grozinsky-Glasberg, S., and Scoazec, J. -Y.

Subjects
medicine.medical_specialty, Biomedical Research, Critical approach, Neuroendocrine Tumors/diagnosis, Endocrinology, Diabetes and Metabolism, Guidelines as Topic, 030209 endocrinology & metabolism, Aggressive disease, Appendix, 030218 nuclear medicine & medical imaging, Unmet needs, Biomedical Research/trends, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Endocrinology, Internal medicine, Epidemiology, medicine, Humans, Intensive care medicine, Appendiceal neuroendocrine neoplasm, Appendiceal Neoplasms/diagnosis, Endocrine and Autonomic Systems, business.industry, Clinical course, Right hemicolectomy, Retrospective cohort study, Prognosis, Carcinoid, Neuroendocrine tumour, Neuroendocrine Tumors, Appendiceal Neoplasms, Human medicine, Appendicectomy, business
Abstract

Appendiceal neuroendocrine neoplasms (ANEN) are mostly discovered coincidentally during appendicectomy and usually have a benign clinical course; thus, appendicectomy alone is considered curative. However, in some cases, a malignant potential is suspected, and therefore additional operations such as completion right hemicolectomy are considered. The existing European Neuroendocrine Tumour Society (ENETS) guidelines provide useful data about epidemiology and prognosis, as well as practical recommendations with regards to the risk factors for a more aggressive disease course and the indications for a secondary operation. However, these guidelines are based on heterogeneous and retrospective studies. Therefore, the evidence does not seem to be robust, and there are still unmet needs in terms of accurate epidemiology and overall prognosis, optimal diagnostic and follow-up strategy, as well as identified risk factors that would indicate a more aggressive surgical approach at the beginning and a more intense follow-up. In this review, we are adopting a critical approach of the ENETS guidelines and published series for ANEN, focusing on the above-noted “grey areas”.

Published
2019

2. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Author

O'Toole, D., Grossman, A., Gross, D., Fave, G. D., Barkmanova, J., O'Connor, J., Pape, U. F., Plöckinger, U., Åkerström, G., Annibale, B., Arnold, R., Bajetta, E., Chen, Y. J., Costa, F., Couvelard, A., Davar, J., Herder, W. D., Eriksson, B., Falconi, M., Ferone, D., Gustafsson, B., Hyrdel, R., Ivan, D., Kaltsas, G., Kianmanesh, R., Klöppel, G., Knigge, U. P., Komminoth, P., Kos Kudla, B., Kwekkeboom, D., Lebtahi, R., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Öberg, K., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, Aldo, Scheidhauer, K., Scoazec, J. Y., Sundin, A., Szpak, W., Taal, B., Vitek, P., Vullierme, M. P., and Wiedenmann, B.

Subjects
Endocrinology, Diabetes and Metabolism, Diagnostic accuracy, insulinoma, Neuroendocrine tumors, Bioinformatics, secretin, 0302 clinical medicine, Endocrinology, immune system diseases, cancer diagnosis, conference paper, Biochemical markers, biology, Urinary 5-hydroxyindoleacetic acid, Chromogranin A, Fasting, Hydroxyindoleacetic Acid, Diabetes and Metabolism, Neuroendocrine Tumors, priority journal, 030220 oncology & carcinogenesis, diagnostic accuracy, 5 hydroxyindoleacetic acid, neuroendocrine tumor, hormones, hormone substitutes, and hormone antagonists, Neuroendocrine tumor test, musculoskeletal diseases, medicine.medical_specialty, Standard of care, MEDLINE, 610 Medicine & health, 030209 endocrinology & metabolism, 03 medical and health sciences, Cellular and Molecular Neuroscience, Patient information, Internal medicine, gastrin, medicine, Humans, biochemistry, human, Insulinoma, Gastrinoma, gastrinoma, Endocrine and Autonomic Systems, business.industry, practice guideline, biochemical marker, chromogranin A, hypoglycemia, patient information, medicine.disease, body regions, biology.protein, 570 Life sciences, Biomarkers, business
Abstract

Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called “general tumor markers.” The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90%. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.

Published
2017
Full Text
View/download PDF

3. Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Author

Lipinski M., Rydzewska G., Foltyn W., Andrysiak-Mamos E., Baldys-Waligorska A., Bednarczuk T., Blicharz-Dorniak J., Bolanowski M., Boratyn-Nowicka A., Borowska M., Cichocki A., Cwikla J. B., Falconi M., Handkiewicz-Junak D., Hubalewska-Dydejczyk A., Jarzab B., Junik R., Kajdaniuk D., Kaminski G., Kolasinska-Cwikla A., Kowalska A., Krol R., Krolicki L., Kunikowska J., Kusnierz K., Lampe P., Lange D., Lewczuk-Myslicka A., Lewinski A., Londzin-Olesik M., Marek B., Nasierowska-Guttmejer A., Nowakowska-Dulawa E., Pilch-Kowalczyk J., Poczkaj K., Rosiek V., Ruchala M., Sieminska L., Sowa-Staszczak A., Starzynska T., Steinhof-Radwanska K., Strzelczyk J., Sworczak K., Syrenicz A., Szawlowski A., Szczepkowski M., Wachula E., Zajecki W., Zemczak A., Zgliczynski W., Kos-Kudla B., Lipinski, M., Rydzewska, G., Foltyn, W., Andrysiak-Mamos, E., Baldys-Waligorska, A., Bednarczuk, T., Blicharz-Dorniak, J., Bolanowski, M., Boratyn-Nowicka, A., Borowska, M., Cichocki, A., Cwikla, J. B., Falconi, M., Handkiewicz-Junak, D., Hubalewska-Dydejczyk, A., Jarzab, B., Junik, R., Kajdaniuk, D., Kaminski, G., Kolasinska-Cwikla, A., Kowalska, A., Krol, R., Krolicki, L., Kunikowska, J., Kusnierz, K., Lampe, P., Lange, D., Lewczuk-Myslicka, A., Lewinski, A., Londzin-Olesik, M., Marek, B., Nasierowska-Guttmejer, A., Nowakowska-Dulawa, E., Pilch-Kowalczyk, J., Poczkaj, K., Rosiek, V., Ruchala, M., Sieminska, L., Sowa-Staszczak, A., Starzynska, T., Steinhof-Radwanska, K., Strzelczyk, J., Sworczak, K., Syrenicz, A., Szawlowski, A., Szczepkowski, M., Wachula, E., Zajecki, W., Zemczak, A., Zgliczynski, W., and Kos-Kudla, B.

Subjects
Male, Duodenum, Stomach, Disease Management, Guidelines, Medical Oncology, Neuroendocrine Tumors, Endocrinology, Duodenal Neoplasms, Stomach Neoplasms, Neuroendocrine neoplasms, Gastrinoma, Humans, Female, Therapy, Poland, Diagnostics, Societies, Medical
Abstract

This paper presents the updated Polish Neuroendocrine Tumour Network expert panel recommendations on the management of neuroendocrine neoplasms (NENs) of the stomach and duodenum, including gastrinoma. The recommendations discuss the epidemiology, pathogenesis, and clinical presentation of these tumours as well as their diagnosis, including biochemical, histopathological, and localisation diagnoses. The principles of treatment are discussed, including endoscopic, surgical, pharmacological, and radionuclide treatments. Finally, there are also recommendations on patient monitoring.

Published
2017

4. Neuroendocrine neoplasms of the small intestine and appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Author

Bednarczuk T., Bolanowski M., Zemczak A., Baldys-Waligorska A., Blicharz-Dorniak J., Boratyn-Nowicka A., Borowska M., Cichocki A., Cwikla J. B., Falconi M., Foltyn W., Handkiewicz-Junak D., Hubalewska-Dydejczyk A., Jarzab B., Junik R., Kajdaniuk D., Kaminski G., Kolasinska-Cwikla A., Kowalska A., Krol R., Krolicki L., Kunikowska J., Kusnierz K., Lampe P., Lange D., Lewczuk-Myslicka A., Lewinski A., Lipinski M., Londzin-Olesik M., Marek B., Nasierowska-Guttmejer A., Nowakowska-Dulawa E., Palucki J., Pilch-Kowalczyk J., Rosiek V., Ruchala M., Sieminska L., Sowa-Staszczak A., Starzynska T., Steinhof-Radwanska K., Strzelczyk J., Sworczak K., Syrenicz A., Szawlowski A., Szczepkowski M., Wachula E., Zajecki W., Zgliczynski W., Kos-Kudla B., Bednarczuk, T., Bolanowski, M., Zemczak, A., Baldys-Waligorska, A., Blicharz-Dorniak, J., Boratyn-Nowicka, A., Borowska, M., Cichocki, A., Cwikla, J. B., Falconi, M., Foltyn, W., Handkiewicz-Junak, D., Hubalewska-Dydejczyk, A., Jarzab, B., Junik, R., Kajdaniuk, D., Kaminski, G., Kolasinska-Cwikla, A., Kowalska, A., Krol, R., Krolicki, L., Kunikowska, J., Kusnierz, K., Lampe, P., Lange, D., Lewczuk-Myslicka, A., Lewinski, A., Lipinski, M., Londzin-Olesik, M., Marek, B., Nasierowska-Guttmejer, A., Nowakowska-Dulawa, E., Palucki, J., Pilch-Kowalczyk, J., Rosiek, V., Ruchala, M., Sieminska, L., Sowa-Staszczak, A., Starzynska, T., Steinhof-Radwanska, K., Strzelczyk, J., Sworczak, K., Syrenicz, A., Szawlowski, A., Szczepkowski, M., Wachula, E., Zajecki, W., Zgliczynski, W., and Kos-Kudla, B.

Subjects
Male, Disease Management, Small intestine, Appendix, Guidelines, Somatostatin analogues, Medical Oncology, Neuroendocrine Tumors, Endocrinology, Carcinoid syndrome, Radioisotope therapy, Neuroendocrine neoplasms, Intestinal Neoplasms, Humans, Female, Everolimus, PRRT, Poland, Societies, Medical
Abstract

This study presents the revised Polish guidelines regarding the management of patients suffering from neuroendocrine neoplasms (NENs) of the small intestine and appendix. The small intestine, especially the ileum, is the most common location for these neoplasms. Most are well differentiated and slow growing. Their symptoms may be atypical, which can result in delayed or accidental diagnosis. Appendicitis is usually the first manifestation of NEN in this location. Typical symptoms of carcinoid syndrome occur in approximately 20-30% of patients suffering from small intestinal NENs with distant metastases. The main cause of death in patients with carcinoid syndrome is carcinoid heart disease. The most useful laboratory test is the determination of chromogranin A, while concentration of 5-hydroxyindoleacetic acid is helpful in the diagnostics of carcinoid syndrome. For visualisation, ultrasound, computed tomography, magnetic resonance imaging, colonoscopy, video capsule endoscopy, double-balloon enteroscopy, and somatostatin receptor scintigraphy may be used. A detailed his-tological report is crucial for the proper diagnostics and therapy of NENs of the small intestine and appendix. The treatment of choice is surgical management, either radical or palliative. The pharmacological treatment of the hormonally active and non-active small intestinal NENs as well as NENs of the appendix is based on long-acting somatostatin analogues. In patients with generalised NENs of the small intestine in progress during the SSA treatment, with good expression of somatostatin receptors, the first-line treatment should be radio-isotope therapy, while targeted therapies, such as everolimus, should be considered afterwards. When the above therapies are exhausted, in certain cases chemotherapy may be considered.

Published
2017

5. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

Author

Falconi, M, Eriksson, B, Kaltsas, G, Bartsch, D K, Capdevila, J, Caplin, M, Kos-Kudla, B, Kwekkeboom, D, Rindi, G, Klöppel, G, Reed, N, Kianmanesh, R, Jensen, R T, Ferone, D, and Radiology & Nuclear Medicine

Subjects
Settore MED/08 - ANATOMIA PATOLOGICA, Endocrine and Autonomic Systems, business.industry, Endocrinology, Diabetes and Metabolism, Non functional, Europe, Humans, Neuroendocrine Tumors, Pancreatic Neoplasms, MEDLINE, Disease, Guideline, Neuroendocrine tumors, Bioinformatics, medicine.disease, Pancreatic Neuroendocrine Neoplasm, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Endocrinology, 030220 oncology & carcinogenesis, Medicine, 030211 gastroenterology & hepatology, business
Abstract

Only advances that occurred from 2011–2014 that either strengthen the previous 2011 guidelines [1;2] or lead to changes or additional guidelines are reviewed here. Advances and modifications in the treatment of advanced metastatic disease is only briefly dealt with here as it is covered in a separate chapter, similar to the 2011 guideline format [3]. The format used here is the same as used in the 2011 guidelines with page references to the appropriate section inserted [1;2] and this document is meant as a supplement to these guidelines and does not reiterate all of the points made in the previous guidelines, only changes, supporting findings or modifications of the 2011 guidelines are thus covered here. As in the previous F-p-NET guidelines [1], the F-p-NETs will be considered in three groups: the more frequent gastrinomas and insulinomas considered independently and all the rare functional p-NETs (RFTs) considered together and as a separate category (Annex 1 and Table 1). Table 1 Functional Pancreatic endocrine tumors [F-p-NET] syndromes

Published
2016
Full Text
View/download PDF

6. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Author

M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg, T. Steinmüller, M. Anlauf, B. Wiedenmann, R. Salazar, B. C. Conference Anlauf M, Arnold R, Bartsch D, Baudin E, Baum R, Brandi ML, Cadiot G, Costa F, Caplin M, Couvelard A, de Herder W, Delle Fave G, Denecke T, Eriksson B, Gress T, Gross D, Grossman A, Jensen R, Kaltsas G, Kelestimur F, Kianmanesh R, Klöppel G, Klose KJ, Knigge U, Komminoth P, Kos Kudla B, Krenning E, Kwekkeboom D, Lopes JM, Niederle B, Nilsson O, Öberg K, O'Connor J, O'Toole D, Pape UF, Papotti M, Pascher A, Pavel M, Perren A, Plöckinger U, Rindi G, Ruszniewski P, Salazar R, Sasano H, Sauvanet A, Scoazec JY, Steinmüller T, Sundin A, Taal B, Tomassetti P, Van Cutsem E, Vullierme MP, Wiedenmann B., FALCONI , MASSIMO, M., Pavel, E., Baudin, A., Couvelard, E., Krenning, K., Öberg, T., Steinmüller, M., Anlauf, B., Wiedenmann, R., Salazar, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, Wiedenmann, B., and Radiology & Nuclear Medicine

Subjects
medicine.medical_specialty, animal structures, Endocrinology, Diabetes and Metabolism, Intestinal Neoplasm, Neuroendocrine tumors, Biology, digestive system, Cellular and Molecular Neuroscience, Endocrinology, stomatognathic system, Internal medicine, Intestinal Neoplasms, medicine, Humans, Endocrine and Autonomic Systems, Liver Neoplasms, fungi, Midgut, Hindgut, Foregut, medicine.disease, Neuroendocrine Tumors, embryonic structures, Unknown primary, Neoplasms, Unknown Primary
Abstract

ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Published
2012
Full Text
View/download PDF

7. ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

Author

U. Pape, A. Perren, B. Niederle, D. Gross, T. Gress, F. Costa, R. Arnold, T. Denecke, U. Plöckinger, R. Salazar, A. Grossman, B. C. Conference Anlauf M, Arnold R, Bartsch D, Baudin E, Baum R, Brandi ML, Cadiot G, Costa F, Caplin M, Couvelard A, de Herder W, Delle Fave G, Denecke T, Eriksson B, Gress T, Gross D, Grossman A, Jensen R, Kaltsas G, Kelestimur F, Kianmanesh R, Klöppel G, Klose KJ, Knigge U, Komminoth P, Kos Kudla B, Krenning E, Kwekkeboom D, Lopes JM, Niederle B, Nilsson O, Öberg K, O'Connor J, O'Toole D, Pape UF, Papotti M, Pascher A, Pavel M, Perren A, Plöckinger U, Rindi G, Ruszniewski P, Salazar R, Sasano H, Sauvanet A, Scoazec JY, Steinmüller T, Sundin A, Taal B, Tomassetti P, Van Cutsem E, Vullierme MP, Wiedenmann B., FALCONI , MASSIMO, Erasmus MC other, U., Pape, A., Perren, B., Niederle, D., Gro, T., Gre, F., Costa, R., Arnold, T., Denecke, U., Plöckinger, R., Salazar, A., Grossman, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, and Wiedenmann, B.

Subjects
medicine.medical_specialty, Endocrine and Autonomic Systems, business.industry, Endocrinology, Diabetes and Metabolism, General surgery, University hospital, Appendix, Appendiceal neoplasms, Neuroendocrine Tumors, Cellular and Molecular Neuroscience, Jejunum, Endocrinology, medicine.anatomical_structure, Appendiceal Neoplasms, Ileum, Internal medicine, Intestinal Neoplasms, neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas, medicine, Humans, business
Abstract

a Division of Hepatology and Gastroenterology, Department of Internal Medicine, Campus Virchow-Klinikum, Charite-Universitatsmedizin Berlin, Berlin , Germany; b Department of Pathology, Universitatsspital, Zurich , Switzerland; c Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna , Austria; d Department of Endocrinology and Metabolism, Hadassah University Hospital, Jerusalem , Israel; e Department of Internal Medicine, Philipps University, Marburg , Germany; f Hopital Sirio Libanes, Centro de Oncologia, Sao Paulo , Brazil; g Department of Radiology, Campus Virchow-Klinikum, Charite, University Medicine Berlin, Berlin , Germany; h Department of Oncology, Institut Catala d’Oncologia (IDIBELL), Barcelona , Spain; i Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford , UK

Published
2012
Full Text
View/download PDF

8. Recommendations for management of patients with neuroendocrine liver metastases

Author

Andrea, Frilling, Modlin, Irvin M., Mark, Kidd, Christopher, Russell, Stefan, Breitenstein, Riad, Salem, Dik, Kwekkeboom, Wan yee Lau, Catherine, Klersy, Valerie, Vilgrain, Brian, Davidson, Mark, Siegler, Martyn, Caplin, Enrico, Solcia, Richard, Schilsky, Adam, R, Akerstrom, G, Belghiti, J, Breitenstein, S, Clavien, Pa, Frilling, A, Gustafsson, B, Krenning, E, Modlin, Im, Norton, J, Öberg, K, Poston, G, Ruszniewski, P, Tait, P, Toogood, G, Russell, C, Bouvier, C, Jarecki, A, Klersy, C, Lau, Wj, Siegler, M, Rindi, G, Kidd, M, Vilgrain, V, Baum, Rp, Heaton, N, Garden, J, Fan, St, Van Gulik, T, Sipperstein, A, Kwekkeboom, D, Caplin, M, Lawrence, B, de Herder, W, Ito, T, Perren, A, Davidson, B, Klimstra, Ds, Kloppel, G, Scarpa, A, Meyer, T, Knuth, A, Chen, H, Van Cutsem, E, Pavel, Me, Kos Kudla, B, Conlon, K, Imamura, M, Kaltsas, G, Broering, D, Wiedenmann, B, Al Nahhas, A, Lodge, P, Cosimelli, M, Grazi, G, Tang, Lh, Salazar, R, Grossman, Ab, Dejong, C, Gores, G, Nagorney, Dm, Mazzaferro, V, Jensen, R, Lesurtel, M, Falconi, M, Hellmann, P, O'Toole, D, Olauson, M, Le Treut, Y, Burroughs, Ak, Valle, J, Kianmanesch, R, Sowa Staszczak, A, Milicevic, M, Lencioni, RICCARDO ANTONIO, Ramage, J, Sangro, B, Kennedy, A, Bester, L, Salem, R, Sharma, R, Parks, R, Bodei, L, Muller Brand, J, Kvols, L, Manas, D, Ramos, J, Wasan, H., Frilling, Andrea, Modlin Irvin, M., Kidd, Mark, Russell, Christopher, Breitenstein, Stefan, Salem, Riad, Kwekkeboom, Dik, Lau Wan, Yee, Klersy, Catherine, Vilgrain, Valerie, Davidson, Brian, Siegler, Mark, Caplin, Martyn, Solcia, Enrico, Schilsky, Richard, Falconi, Massimo, Andrea, Frilling, Modlin, Irvin M., Mark, Kidd, Christopher, Russell, Stefan, Breitenstein, Riad, Salem, Dik, Kwekkeboom, Wan-yee, Lau, Catherine, Klersy, Valerie, Vilgrain, Brian, Davidson, Mark, Siegler, Martyn, Caplin, Enrico, Solcia, Richard, Schilsky, for the Working Group on Neuroendocrine Liver Metastases,, Grazi, G., Radiology & Nuclear Medicine, and Internal Medicine

Subjects
medicine.medical_specialty, Biopsy, MEDLINE, clinical practice guidelines, hepatic metastases, prognostic factors, surgical management, Neuroendocrine tumors, surgical management, Systemic therapy, NO, medicine, Hepatectomy, Humans, hepatic metastases, Intensive care medicine, medicine.diagnostic_test, business.industry, Liver Neoplasms, prognostic factors, Interventional radiology, medicine.disease, Neoplastic Cells, Circulating, Neoadjuvant Therapy, Surgery, Clinical Practice, Neuroendocrine Tumors, Oncology, Genomic information, business, Working group, clinical practice guidelines
Abstract

Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research. © 2014 Elsevier Ltd.

Published
2014
Full Text
View/download PDF

9. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography

Author

Plöckinger, U., Gustafsson, B., Ivan, D., Szpak, W., Davar, J., Åkerstrom, G., Annibale, B., Arnold, R., Bajetta, E., Barkmanova, J., Chen, Y. J., Costa, F., Couvelard, A., Herder, W. D., Fave, G. D., Eriksson, B., Falconi, M., Ferone, D., Gross, D., Grossman, A., Hyrdel, R., Kaltsas, G., Kianmanesh, R., Klöppel, G., Knigge, U. P., Komminoth, P., Kos Kudla, B., Kwekkeboom, D., Lebtahi, R., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Öberg, K., O'Connor, J., O'Toole, D., Pape, U. F., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, Aldo, Scheidhauer, K., Scoazec, J. Y., Sundin, A., Taal, B., Vitek, P., Vullierme, M. P., and Wiedenmann, B.

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Carcinoid tumors, MEDLINE, Carcinoid Heart Disease, carcinoid syndrome, Diagnostic accuracy, Disease, Neuroendocrine tumors, Cellular and Molecular Neuroscience, Endocrinology, cancer diagnosis, Internal medicine, Humans, echocardiography, Medicine, human, medical society, conference paper, medical documentation, Endocrine and Autonomic Systems, business.industry, practice guideline, Medical practice, diagnostic accuracy, medical practice, neuroendocrine tumor, patient information, priority journal, medicine.disease, Medical documents, Neuroendocrine Tumors, business, Carcinoid syndrome
Abstract

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors : echocardiography.

Published
2009
Full Text
View/download PDF

10. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

Author

Kwekkeboom, D. J., Krenning, E. P., Lebtahi, R., Komminoth, P., Kos-Kudla, B., De Herder, W. W., Plockinger, U., Akerstrom, G., Annibale, B., Arnold, R., Bajetta, E., Barkmanova, J., Chen, Y. -J., Costa, F., Couvelard, A., Davar, J., Delle Fave, G., Eriksson, B., Falconi, M., Ferone, D., Gross, D., Grossman, A., Gustafsson, B., Hyrdel, R., Ivan, D., Kaltsas, G., Kianmanesh, R., Kloppel, G., Knigge, U. -P., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Oberg, K., O'Connor, J., O'Toole, D., Pape, U. -F., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, A., Scheidhauer, K., Scoazec, J. -Y., Sundin, A., Szpak, W., Taal, B., Vitek, P., Vullierme, M. -P., Wiedenmann, B., Radiology & Nuclear Medicine, and Internal Medicine

Subjects
Peptide receptor, Endocrinology, Diabetes and Metabolism, Treatment outcome, 1 4 7 10 tetraacetic acid, Neuroendocrine tumors, Endocrinology, Receptors, comparative study, conference paper, peptide receptor radionuclide therapy, 1 4 7 10 tetraazacyclododecane, GEPNET, Carcinoids, clinical trial, yttrium 90, peptide, unclassified drug, drug dose comparison, Somatostatin, priority journal, neuroendocrine tumor, medicine.medical_specialty, Receptors, Peptide, Radiolabeled somatostatin analogues, lutetium 177, octreother, octreotide[3 tyrosine], pentetreotide in 111, radioisotope, somatostatin derivative, cancer radiotherapy, drug dose escalation, human, multiple cycle treatment, practice guideline, treatment duration, treatment outcome, Cellular and Molecular Neuroscience, Internal medicine, medicine, Humans, Radioisotopes, Radiotherapy, Endocrine and Autonomic Systems, business.industry, Guideline, Neuroendocrine Tumors, medicine.disease, Clinical trial, Cancer Radiotherapy, Radionuclide therapy, business
Abstract

The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT. This guideline also makes recommendations on what minimal patient, tumor, and treatment outcome characteristics should be reported for PRRT in order to make comparisons between studies possible. It is not this guideline's aim to give specific recommendations on the use of specific radiolabeled somatostatin analogs for PRRT because different analogs are being used, and their availability depends on national law and local permissions. Copyright (C) 2009 S. Karger AG, Basel

Published
2009

11. Circadian rhythm of androstendione and free testosterone in asthmatic women with postmenopausal hormone therapy

Author

Kos-Kudla, B., Ostrowska, Z., Marek, B., Kajdaniuk, D., Mariusz Nowak, Kudla, M., Glogowska-Szelag, J., and Lisik, V.

Subjects
Case-Control Studies, Administration, Inhalation, Estrogen Replacement Therapy, Androstenedione, Humans, Female, Testosterone, Anti-Asthmatic Agents, Middle Aged, Glucocorticoids, Asthma, Circadian Rhythm
Abstract

of this study was to assess daily rhythm of androstendione (delta4alpha) and free testosterone (FT) levels in postmenopausal asthmatic women before and after hormonal replacement therapy and the influence of inhaled glucocorticosteroids (GC).54 asthmatic and 20 healthy postmenopausal women (aged 48-59) before and after 6 months of estrogen plus progestin therapy (EPT) were studied. Hormone concentrations in serum (delta4alpha and FT) were assessed with the use of RIA method. Statistical analysis of the circadian rhythm was performed with the use of cosinor test according to Halberg et alCosinor analysis of delta4alpha and FT secretion during the day showed existence of daily rhythm in three studied groups before as well as after postmenopausal hormone therapy (HT). A statistically significant decrease of circadian concentrations of delta4alpha and FT in groups of patients treated with GC was observed. Changes in amplitude of delta4alpha and FT rhythm between studied groups were not observed. However, displacement of rhythm acrophase of studied hormones in asthmatic women in comparison to control group before and after HT was shown. No significant differences in circadian values of delta4alpha and FT concentrations before HT use compared to values after HT were shown.Postmenopausal asthmatic women show diminished circadian concentrations of androstendione and free testosterone in serum caused among other things by inhalative GC. Postmenopausal hormone therapy did not influence any changes in function of studied endocrine organs.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results